A practitioner's guide to the four documentation issues most firms working Depo-Provera cases have not yet examined at scale.

The Depo-Provera litigation is in active discovery with bellwether trials on the horizon. Product classifications that do not hold up to scrutiny, diagnosis dates that are not the earliest defensible dates, treatment distributions that look different from what intake suggested, and timelines that only become visible when you read the full record for every case simultaneously. These issues do not surface from intake forms. They surface when someone looks systematically across the full record for every case in the inventory.

This guide will show you:

• - Why product classification in Depo-Provera is rarely as straightforward as the documentation suggests, and what the 2005 date means for your inventory
• - How the path to a confirmed meningioma diagnosis often starts months or years before the formal diagnosis date, and why that gap matters for how your firm dates the injury
• - Why treatment rates in this litigation are lower than most firms expect when they sign cases, and what that means for how cases will be valued
• - The relationship between last product use date and diagnosis date, and why that timeline requires structured extraction to surface at scale
• - The questions every firm should be able to answer about their Depo-Provera docket before settlement criteria are set